Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D08KPA
|
|||
| Former ID |
DNCL002098
|
|||
| Drug Name |
BZL-101
|
|||
| Indication | Breast cancer [ICD-11: 2C60-2C65] | Phase 2 | [1] | |
| Company |
Bionovo
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Cell cycle (CC) | Target Info | Inhibitor | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT00907959) A Clinical Trial Assessing Safety and Efficacy of BZL101 for Metastatic Breast Cancer. U.S. National Institutes of Health. | |||
| REF 2 | BZL101, a phytochemical extract from the Scutellaria barbata plant, disrupts proliferation of human breast and prostate cancer cells through distinct mechanisms dependent on the cancer cell phenotype. Cancer Biol Ther. 2010 Aug 15;10(4):397-405. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.